Ascentage Pharma trustee buys 100,000 shares for RSU plan

Ascentage Pharma Group International reports that the trustee of its 2022 RSU Scheme has bought existing shares on the market to fund future share awards.

Rhea-AI Filing Summary

Ascentage Pharma Group International reports that the trustee of its 2022 RSU Scheme has bought existing shares on the market to fund future share awards. On May 27, 2026, the trustee purchased 100,000 shares, about 0.0268% of issued shares, for total consideration of HK$3,977,000 at an average price of about HK$39.77 per share.

Following this transaction, the trustee holds 2,265,000 shares for the scheme. These shares are held under a trust, and the trustee will not exercise voting rights attached to them.

Key Figures

Purchased shares: 100,000 shares Purchase proportion: Approximately 0.0268% Total consideration: HK$3,977,000 +2 more

5 metrics

Purchased shares 100,000 shares On-market purchase on May 27, 2026 for 2022 RSU Scheme

Purchase proportion Approximately 0.0268% Percentage of total issued shares at announcement date

Total consideration HK$3,977,000 Aggregate amount paid for 100,000 purchased shares, excluding related expenses

Average price per share Approximately HK$39.77 Average consideration per purchased share, excluding expenses and levies

Total RSU scheme holdings 2,265,000 shares Existing shares held by trustee for 2022 RSU Scheme after purchase

Key Terms

2022 RSU Scheme, Trustee, on-market, independent non-executive Directors

4 terms

2022 RSU Scheme financial

"for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon vesting"

Trustee financial

"the Trustee purchased a total of 100,000 existing Shares on-market"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

on-market financial

"the Trustee purchased a total of 100,000 existing Shares on-market"

On-market describes buying or selling shares directly through a public stock exchange at the current market price, rather than by a private or negotiated deal. Like buying an item from a store at the posted price instead of haggling privately, on-market trades happen quickly, are visible to other investors, and can move the stock price, so they affect liquidity and provide a transparent signal about supply and demand.

independent non-executive Directors financial

"as independent non-executive Directors"

Independent non-executive directors are board members who do not work for the company and have no significant financial or personal ties to its managers; they do not run day-to-day operations but attend board meetings to oversee strategy and decisions. For investors, they matter because they act like outside referees or impartial advisors who help prevent self-dealing, challenge management when needed, and boost confidence that the company’s decisions serve shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascentage Pharma Group International (AAPG) announce in this 6-K?

Ascentage Pharma announced that the trustee of its 2022 RSU Scheme purchased existing shares on the market. The trustee bought 100,000 shares on May 27, 2026 to satisfy restricted share units when they vest for eligible participants.

How many Ascentage Pharma (AAPG) shares did the trustee purchase and at what price?

The trustee bought 100,000 existing shares on May 27, 2026. Total consideration was HK$3,977,000, implying an average price of about HK$39.77 per share, excluding expenses, levies, brokerage, taxes, duties and other related charges.

What proportion of Ascentage Pharma’s issued shares do the purchased RSU shares represent?

The 100,000 purchased shares represent approximately 0.0268% of Ascentage Pharma’s total issued shares as of the announcement date. This indicates the transaction is small relative to the company’s overall share capital base.

How many Ascentage Pharma shares does the trustee now hold for the 2022 RSU Scheme?

Immediately after this purchase, the trustee held 2,265,000 existing shares for the 2022 RSU Scheme. These shares are reserved to satisfy restricted share units upon vesting and are held under trust arrangements between the company and the trustee.

Does the trustee vote the Ascentage Pharma shares held for the 2022 RSU Scheme?

No. The announcement states that the trustee shall not exercise voting rights attached to the shares it holds on trust. This means those shares are held for employee incentive purposes without affecting voting control at shareholder meetings.

Were any new awards granted under Ascentage Pharma’s 2022 RSU Scheme in this announcement?

The company states that, as of this announcement, no further awards were granted beyond the initial grant and previously disclosed further grants. The May 27, 2026 transaction only concerns purchasing shares to satisfy already granted RSUs in future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 08:29 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of May 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On May 27, 2026, Ascentage Pharma Group International issued an announcement entitled “Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme”. A copy of the press release is furnished as Exhibit 99.1.

1

INDEX TO EXHIBITS

Exhibit Number		Exhibit Title
99.1		Announcement dated May 27, 2026

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: May 27, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

Exhibit 99.1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

VOLUNTARY ANNOUNCEMENT

PURCHASE OF SHARES BY THE TRUSTEE

FOR THE PURPOSE OF THE 2022 RSU SCHEME

This announcement is made by Ascentage Pharma Group International (the “Company”) on a voluntary basis. Reference is made to the announcements of the Company dated June 23, 2022, July 14, 2022, October 21, 2022, October 25, 2022, October 26, 2022, October 27, 2022, October 28, 2022, October 31, 2022, May 8, 2023, November 13, 2023, November 14, 2023, November 16, 2023, February 2, 2024, September 2, 2024, October 25, 2024, March 31, 2025, April 8, 2025, April 30, 2025, June 27, 2025, November 27, 2025, December 30, 2025, April 20, 2026 and April 30, 2026 (the “Announcements”) in relation to, among other things, (i) the adoption of and amendments to the 2022 RSU Scheme; (ii) the initial grant and the further grants of the 2022 Awards thereunder; and (iii) the purchase of existing Shares by the Trustee on-market for the purpose of the 2022 RSU Scheme. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

On May 27, 2026, the Trustee purchased a total of 100,000 existing Shares (the “Purchased Shares”) on-market for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon vesting. Details of the Purchased Shares and the latest information about the Shares held by the Trustee under the Scheme are as follows:

Purchase date	:	May 27, 2026
Total number of the Purchased Shares	:	100,000 Shares
Percentage of the Purchased Shares to the total number of issued Shares as at the date of this announcement	:	Approximately 0.0268%
Total consideration paid for the Purchased Shares (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	HK$3,977,000
Average consideration per Purchased Share (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	Approximately HK$39.77
Total number of existing Shares purchased by the Trustee on-market for the purpose of the 2022 RSU Scheme immediately after the aforesaid purchases	:	2,265,000 Shares

The Purchased Shares are currently held by the Trustee in accordance with the 2022 RSU Scheme Rules and the terms of the trust deed entered into between the Company and the Trustee. The Trustee shall not exercise the voting rights attached to the Shares held on trust by it. As at the date of this announcement, no further grant of Awards has been made pursuant to the 2022 RSU Scheme apart from the initial grant of the 2022 Awards on June 23, 2022 and the further grants of the 2022 Awards on May 4, 2023, September 2, 2024, June 27, 2025, November 26, 2025 and April 20, 2026 as disclosed in the Announcements.

By Order of the Board

Ascentage Pharma Group International Dr.

Yang Dajun

Chairman and Executive Director

Suzhou, People’s Republic of China, May 27, 2026

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote 1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky Note 2, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.

Notes:

1. Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.

2. Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 ANNOUNCEMENT DATED MAY 27, 2026 11.7 KB